Clinical Trial Update: Evoked Responses as Pharmacodynamic Biomarkers in Healthy and Schizophrenic Participants (MK-4334-007) [Phase 1]

View source ↗

Summary

Phase 1 clinical trial update reporting results of evaluating evoked responses as pharmacodynamic biomarkers in healthy participants and individuals with cognit…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cognitive Impairment Associated with Schizophrenia

Drugs mentioned

• MK-4334

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Cognitive Impairment Associated With Schizophrenia | Phase 1 | Status: COMPLETED | Results posted: 2024-11-29